Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 10:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 7,392 matching trials from the live ClinicalTrials.gov search.
Conditions
Heart Block Complete, Heart Block Second Degree
Interventions
Dexamethasone, No Dexamethasone
Drug · Other
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
350 participants
Timeline
2020 – 2029
U.S. locations
12
States / cities
Phoenix, Arizona • San Francisco, California • Denver, Colorado + 9 more
Conditions
Musculoskeletal Injuries
Interventions
PREPARE Initial Clinical Assessment - Pilot (two iterations), PREPARE Initial Clinical Assessment - Pre-Injury (one iteration), PREPARE Initial Clinical Assessment - Post-Injury (up to three iterations), PREPARE Optimized Clinical Assessment
Other
Lead sponsor
Womack Army Medical Center
Federal
Eligibility
18 Years to 44 Years
Enrollment
2,690 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
2
States / cities
Bethesda, Maryland • Fort Liberty, North Carolina
Completed Phase 2 Interventional Results available

Oral Testosterone for the Treatment of Hypogonadism

NCT01717768
Conditions
Hypogonadism
Interventions
TSX-002
Drug
Lead sponsor
TesoRx Pharma, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Neuroendocrine Tumors, Carcinoma, Small Cell Lung, Neuroendocrine Carcinoma
Interventions
PEN-221
Drug
Lead sponsor
Tarveda Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Boston, Massachusetts + 4 more
Conditions
Prostate Cancer
Interventions
GPI-0100, MUC-2-Globo H-KLH conjugate vaccine
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
New York, New York
Conditions
Psoriasis
Interventions
Deucravacitinib, Systemic psoriasis medications, No systemic medications
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
15 Years to 50 Years · Female only
Enrollment
833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Lawrenceville, New Jersey
Completed Phase 2 Interventional Accepts healthy volunteers

Short-Term Oral Mifepristone for Central Serous Chorioretinopathy

NCT02354170
Conditions
Central Serous Chorioretinopathy
Interventions
Mifepristone, Placebo
Drug
Lead sponsor
Roger Goldberg, M.D., MBA
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
2
States / cities
Walnut Creek, California • Boston, Massachusetts
Conditions
Healthy Participants
Interventions
AZD6793, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Glendale, California
Conditions
Solid Tumor, Adult
Interventions
HTI-1066 dose level 1, HTI-1066 dose level 2, HTI-1066 dose level 3, HTI-1066 dose level 4
Drug
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Scottsdale, Arizona • Nashville, Tennessee • Houston, Texas
Conditions
Breast Neoplasms, Obesity
Interventions
Biopsy, Blood draw, Mammogram, MRI
Procedure
Lead sponsor
Tarah J Ballinger, MD
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Carmel, Indiana • Indianapolis, Indiana
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK1292263, GSK1292263 matching placebo, Sitagliptin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Chula Vista, California • Miami, Florida + 4 more
Conditions
Lung Cancer
Interventions
CyPath
Device
Lead sponsor
Biomoda Inc.
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
3
States / cities
Waterbury, Connecticut • Newark, Delaware • Albuquerque, New Mexico
Conditions
Metastatic Breast Cancer, Recurrent Breast Cancer
Interventions
Taselisib, Trastuzumab emtansine, Pertuzumab, Trastuzumab, Paclitaxel
Drug
Lead sponsor
Nancy Lin, MD
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
3
States / cities
Boston, Massachusetts • Nashville, Tennessee
Conditions
Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8
Interventions
Nivolumab, Sorafenib
Biological · Drug
Lead sponsor
Robin Kate Kelley
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Sacramento, California • San Francisco, California
Not yet recruiting No phase listed Observational

IMPACT-Ready Study

NCT07931690
Conditions
Autism Spectrum Disorder, Neurodevelopmental Disorders
Interventions
Not listed
Lead sponsor
Coalition for Aligning Science
Other
Eligibility
0 Years to 18 Years
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2040
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 7 more
Conditions
Colorectal Cancer
Interventions
Atezolizumab, Bevacizumab, Cobimetinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
Aurora, Colorado • New York, New York • Nashville, Tennessee + 1 more
Conditions
Lung Cancer
Interventions
Autologous dendritic cell-adenovirus p53 vaccine, Carboplatin, Etoposide
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Interventions
Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
Drug
Lead sponsor
CARGO Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
31
States / cities
Little Rock, Arkansas • Duarte, California • Los Angeles, California + 24 more
Conditions
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory Myelodysplastic Syndrome
Interventions
NC525
Drug
Lead sponsor
NextCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
11
States / cities
Duarte, California • Miami, Florida • Boston, Massachusetts + 6 more
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
AZD2287, AZD2275, AZD2284
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Palo Alto, California • San Diego, California • Miami, Florida + 9 more
Completed No phase listed Observational

Genomics of Kidney Transplantation

NCT01714440
Conditions
KidneyTransplant Recipients, Simultaneous Kidney/Pancreas Recipients, Kidney Transplant Donor
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
1,552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota
Conditions
Ocular Hypertension, Open Angle Glaucoma
Interventions
OTX-TIC
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Petaluma, California • Torrance, California • Roswell, Georgia + 2 more
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult T-Cell Leukemia/Lymphoma, Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Hematopoietic and Lymphatic System Neoplasm, Hodgkin Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome, Myelofibrosis, Myeloid Neoplasm, Non-Hodgkin Lymphoma, Polycythemia Vera, Small Lymphocytic Lymphoma
Interventions
Fludarabine, Total-Body Irradiation, Donor Lymphocyte Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Hematopoietic Cell Transplantation, Melphalan, Bone Marrow Aspiration and Biopsy, Diagnostic Imaging, Biospecimen Collection
Drug · Radiation · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
1
States / cities
Philadephia, Pennsylvania
Conditions
Primary Myelofibrosis
Interventions
Momelotinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
14
States / cities
Scottsdale, Arizona • Stanford, California • Aurora, Colorado + 11 more